Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Br J Cancer. 2011 Jan 4;104(1):19-23. doi: 10.1038/sj.bjc.6606014. Epub 2010 Nov 30.
FK506 binding protein 51 (FKBP51, also called FKBP5) belongs to a family of immunophilins, FK506 binding proteins (FKBPs). Members of this family are targets for drugs such as rapamycin and cyclosporine. Although FKBP5 shares characteristics with other FKBPs, it also has unique features, especially its role in the regulation of multiple signalling pathways and in tumourigenesis and chemoresistance. In this review, we will focus on the recently discovered role of FKBP5 in cancer aetiology and response to antineoplastic therapy.
FK506 结合蛋白 51(FKBP51,也称为 FKBP5)属于免疫亲和素 FK506 结合蛋白(FKBPs)家族。该家族的成员是雷帕霉素和环孢素等药物的靶点。虽然 FKBP5 与其他 FKBPs 具有共同特征,但它也具有独特的特征,特别是在调节多种信号通路以及在肿瘤发生和化疗耐药中的作用。在这篇综述中,我们将重点介绍 FKBP5 在癌症发病机制和抗肿瘤治疗反应中的最新发现作用。